Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
UTHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$214.52 - $417.82
Previous CloseN/A
Volume58.00K
Average Volume (3M)340.17K
Market Cap
$16.64B
Enterprise Value$14.42B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.7
Beta0.72
Next Earnings
Apr 30, 2025EPS Estimate
6.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)22.77
Shares Outstanding44,644,520
10 Day Avg. Volume410,201
30 Day Avg. Volume340,169
Standard Deviation0.10
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.04
Price to Cash Flow (P/CF)11.00
P/FCF Ratio13.80
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda9.56
Forecast
1Y Price Target
$414.67Price Target Upside8.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
United Therapeutics News
PremiumCompany Announcements
United Therapeutics to Present at J.P. Morgan Conference
---
Bulls Say, Bears Say
Bulls Say
Market PositionTyvaso is the most prescribed prostacyclin in the US, and no near-term erosion in Tyvaso's market share in PAH is expected.
Pipeline AdvancementMultiple potential growth drivers for the commercial business and continued pipeline advancement that investors should watch for.
Revenue GrowthTotal Q3 revenues came in above consensus, supported by beats from Tyvaso and Orenitram.
Bears Say
Clinical Trial RisksThe clinical trial design includes extensive safety and efficacy monitoring, which aims to ensure the success and safety of the procedure for participants.
Financial Model UncertaintyThe success of the UKidney initiative is not yet included in the company's financial model, indicating uncertainty and potential risk for investors.
Potential CompetitionUTHR should be well-prepared for potential entry of competitor LQDA’s Yutrepia in PAH/PH-ILD, given their entrenched presence and robust commercial infrastructure.
---
Ownership Overview
7.08% Insiders
25.89% Mutual Funds
0.54% Other Institutional Investors
38.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $214.52 and its highest was $417.81 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $16.64B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 68 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Oct 30, 2024. The company reported $6.39 earnings per share for the quarter, missing the consensus estimate of $6.523 by -$0.133.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.56.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 44,644,520 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $6.39 in its last earnings report, missing expectations of $6.523. Following the earnings report the stock price went up 2.438%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$414.67 (8.90% Upside)
$414.67 (8.90% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.32%
12-Months-Change
Fundamentals
Return on Equity
18.81%
Trailing 12-Months
Asset Growth
1.42%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTHR Company Deck
---
UTHR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with significant revenue growth across multiple products and the successful completion of a share repurchase program. However, there were some challenges, such as a litigation accrual and a slight decline in international Remodulin revenue.Read More>---
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTHR Stock 12 Month Forecast
Average Price Target
$414.67
▲(8.90% Upside)
Technical Analysis
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+23.89%
reiterated a buy rating 4 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +23.89% per trade.
---